Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ad: Dr Adeodata Kekitiinwa-Rukyalekere, Baylor College of Medicine Children’s Foundation, Uganda
Countries involved: Italy, Kenya, the Netherlands, South Africa, Uganda, United Kingdom, Zimbabwe
Target population(s): Adolescents
Year funded: 2018
EDCTP funding: €7.4 M
Project at a glance
close popup
HomeThe challengeThe projectImpactProject at a glance
EDCTP portfolio: HIV & HIV-associated infections
index
https://publications.edctp.org/international-partnerships-against-infectious-diseases/breather-plus
Transvac 2 is a new virosomal vaccine designed against sarscov2 viruses that are in phase II clinical trials. The transvac 2 vaccine is an innovative compound expected to be helpful in the recent viral pandemic.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163339143
Name, title and organisation of the scientific representative of the project's
coordinator:
Dr. Odile Leroy, Executive Director, European Vaccine Initiative
Tel: +49 1726184821
Fax: +49 6221565727
E-mail: odile.leroy@euvaccine.eu
Project website address: www.transvac.org
Grant Agreement number: FP7-INFRASTRUCTURES-2008-1-228403
Project acronym: TRANSVAC
Project title: European Network of Vaccine Research and Development
Funding Scheme: Combination of Collaborative Project and Coordination and Support
Action
Date of latest version of Annex I against which the assessment will be made: 23
August 2013
Periodic report: Final Report
Period covered: 1 October 2009 – 30 September 2013
https://cordis.europa.eu/docs/results/228403/final1-0-transvac-coordinator-and-consortium-final-report.pdf
108
The Open Vaccine Journal,
2010,
3,
108-1131875-0354/10 2010 Bentham Open
Open Access
Safety of a Virosomal Adjuvanted Influenza Vaccine in Children Suffering from Chronic Disease
G.V. Zuccotti
*
Department of Paediatrics, University of Milan, Luigi Sacco Hospital, Via GB Grassi 74, 20157 Milan, Italy
Abstract:
Children suffering from chronic disease are at increased risk for complications and mortality caused by influenza. Influenza can be most effectively prevented by vaccination. Although recommended for children with chronic disease, vaccination rates remain low in this population. One possible explanation is the parents’ concern that the child’s nunderlying disease may worsen or that adverse events following influenza vaccination may be more severe than in healthy children. Data demonstrating the safety of influenza vaccination in this population are therefore crucial and may help to increase future vaccination rates in children suffering from chronic disease. The present review summarises published data on safety following vaccination with a virosomal adjuvanted influenza vaccine in children suffering from chronic disease compared with healthy children. The vaccine was shown to be immunogenic and safe in four particularly vulner-able populations: children suffering from asthma, cystic fibrosis, diabetes, or HIV infection. No changes in the course of the underlying diseases were observed after vaccination.
relating to or producing an immune response in Childern!!!
Influenza vaccine, virosomes, asthma, cystic fibrosis, HIV, diabetes.
https://www.scribd.com/document/255154981/Safety-of-a-Virosomal-Adjuvanted-Influenza-Vaccine-in-Children
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial
Tracy J Ruckwardt, PhD *
Kaitlyn M Morabito, PhD *
Emily Phung, PhD *
Michelle C Crank, MD *
Pamela J Costner, RN
LaSonji A Holman, FNP
Lauren A Chang
Somia P Hickman, PhD
Nina M Berkowitz, MPH
Ingelise J Gordon, RN
Galina V Yamshchikov, MS
Martin R Gaudinski, MD
Bob Lin
Robert Bailer, PhD
Man Chen, MD
Ana M Ortega-Villa, PhD
Thuy Nguyen
Azad Kumar, PhD
Richard M Schwartz, PhD
Lisa A Kueltzo, PhD
Judith A Stein, MBA
Kevin Carlton, MS
Jason G Gall, PhD
Martha C Nason, PhD
John R Mascola, MD
Grace Chen, MD †
Barney S Graham, MD †
VRC 317 study team
Show less
Show footnotes
Published: April 14, 2021 DOI:https://doi.org/10.1016/S2213-2600(21)00098-9
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159626649
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152799044
Bell palsy following intranasal influenza vaccination
Extract from report of GACVS meeting of 20-21 June 2002, published in the WHO Weekly Epidemiological Record on 22 November 2002
Results from a case–control study and a case-series analysis indicate a significantly increased risk of Bell palsy developing following intranasal immunization with a new vaccine. This inactivated influenza vaccine, composed of influenza antigens in a virosomal formulation with E. coli derived LT adjuvant, was licensed in Switzerland in October 2000. Following spontaneous reports of Bell palsy, the company decided not to market the vaccine during the following season.
In general, the etiology and pathogenesis of Bell palsy remain inadequately understood. The greater risk of Bell palsy following immunization with this vaccine may be due to specific vaccine components such as LT toxin, influenza antigens or virosomes, or simply to use of the intranasal administration route. It is thus possible that such complications of vaccine administration may also apply to other nasal vaccines. GACVS therefore recommends that any novel vaccine for nasal administration should be tested on a sufficiently large number of subjects before licensing and submitted to active post-marketing surveillance studies. Since the average time to onset of Bell palsy following intranasal immunization with this new vaccine was as much as 60–90 days, GACVS recommends that the follow-up period in the context of clinical trials should be routinely extended to 3 months following administration of a new intranasal vaccine.
Full report of GACVS meeting of 20-21 June 2002, published in the WHO Weekly Epidemiological Record on 22 November 2002
https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/bell-s-palsy-following-intranasal-vaccination
SYNAGIS® (PALIVIZUMAB)
â Synagis (palivizumab) is a registered trademark of MedImmune, Inc.
Manufactured by:
.
Co-Marketed by:
.
MedImmune, Inc.
Gaithersburg, MD 20878
U.S. Gov't. License No. 1252
(1-877-633-4411)
Ross Products Division
Abbott Laboratories, Inc.
Columbus, OH 43215-1724
https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/palimed102302LB.pdf
RSV Vaccine Containing 3 D-PHADA ( R ) Adjuvant
Contains this:
Synagis® (palivizumab) is a humanized mouse monoclonal antibody that recognizes an epitope present on both the pre-fusion and on post-fusion conformation of the RSV-F protein; 5C4 is a mouse monoclonal antibody that specifically recognizes the pre-fusion conformation of RSV-F (McLellan, J.S. et al. Science (2013) 340 (6136): 1113). In this example, Synagis® was used to quantify F on intact virus, and the 5C4/ Synagis® ratio to determine the relative concentration of F that is present in the pre-fusion conformation.
https://patentscope.wipo.int/search/en/detail.jsf;jsessionid=F9E307CF24CB19C30379619CE6FC26B8.wapp2nB?docId=WO2016039620&tab=PCTDESCRIPTION
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016039620&tab=PCTBIBLIO
BESTEWIL HOLDING B.V.
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016039620&tab=SEARCHREPORT
Abstract
(EN)
The invention provides virosome preparations from an enveloped virus, in particular from influenza virus, containing an antigen from said virus, and a saponin adjuvant. In particular the invention provides a virosome preparation from influenza virus containing an influenza antigen a QS21, optionally with a sterol. The invention also provides vaccine compositions containing said virosome preparations, methods of preparing said virosome preparations and vaccine containing them.
WO 2005117958 A1 (GLAXOSMITHKLINE BIOLOG SA [BE]; COLLER BETH-ANN [BE]; HENDERICKX VERON) 15 December 2005 (2005-12-15)
1-34
page 8, line 20 - page 10, line 17; claims 1-34
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2005117958&altUrl=http%3A%2F%2Fv3.espacenet.com%2Ftextdoc%3FDB%3DEPODOC%26IDX%3DWO2005117958%26CY%3Dep
22.08
2018 Mymetics : Development of a Virosomal RSV Vaccine Containing 3D-PHAD® Adjuvant: Formulation, Composition, and Long-Term Stability
Purpose :Characterization of virosomes, in late stage preclinical development as vaccines for Respiratory Syncytial Virus (RSV), with a membrane-incorporated synthetic monophosphoryl lipid A, 3D-PHAD® adjuvant.
https://www.biopole.ch/mymetics-development-of-a-virosomal-rsv-vaccine-containing-3d-phad-adjuvant-formulation-composition-and-long-term-stability/
Sponsors and Collaborators
University of Saskatchewan
Government of Canada
Government of Saskatchewan
Vaccine Formulation Institute (VFI)
SEPPIC
Vaccine Formulation Institute (VFI), Switzerland
https://clinicaltrials.gov/ct2/show/NCT04702178?cond=NCT04702178
TRANSVAC M3 course: Adjuvants and vaccine formulation, 2021 ...
validate.web.ox.ac.uk › event › transvac-m3-course
Location: Vaccine Formulation Institute (VFI), Switzerland. Deadline for applications: 1 Nov 2020 TRANSVAC is a collaborative infrastructure project funded by the European Commission (EC), initially under the 7th Framework Programme (FP7) and currently under Horizon 2020.
https://validate.web.ox.ac.uk/event/transvac-m3-course-adjuvants-and-vaccine-formulation-2021
TORONTO and CAMBRIDGE, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today initiation of a program to construct and test a multivalent peptide vaccine for Alzheimer’s disease (AD). The critical first steps in vaccine development will be carried out by VIDO-InterVac, a global leader in vaccine research and development.
https://apnews.com/press-release/globe-newswire/virus-outbreak-toronto-executive-changes-north-america-immunizations-6722f9337b641ca8d2801b3ee136e49a
Contagious Bovine and Caprine Pleuropneumonia: a research ...
pubmed.ncbi.nlm.nih.gov › 33580051
6 Vaccine and Infectious Disease Organization-International Vaccine Centre, University of Saskatchewan, Saskatoon, SK, Canada. 7 Friedrich-Loeffler-Institute - Federal Research Institute for Animal Health, Jena, Germany. 8 Bill & Melinda Gates Foundation, Seattle, WA, USA. 9 Institute of Veterinary Bacteriology, University of Bern, Bern ...
https://pubmed.ncbi.nlm.nih.gov/33580051/
The researchers recommend that special efforts be put into virosome-based viral vaccine improvements, such as the Transvac 2, a new virosomal vaccine designed against SARS-CoV-2 viruses. Transvac 2 is in phase ?? clinical trials. It is an innovative compound expected to be helpful in the recent viral pandemic.
In this review, the authors addressed important questions on the nature, preparation and popularity of the virosomes, highlighting their significance in the wake of COVID-19.
Journal reference:
Asadi, Khatereh and Ahmad Gholami. (2021) Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review. International Journal of Biological Macromolecules. https://doi.org/10.1016/j.ijbiomac.2021.04.005, https://www.sciencedirect.com/science/article/pii/S0141813021007601
Khatereh Asadi's research while affiliated with Shiraz University of Medical Sciences and other places
Shiraz University of Medical Sciences (SUMS) (Persian: ??????? ???? ????? ????? Daneshgah-e Olum Pezeshki-e Shiraz?) is a public medical school located in Shiraz, Iran. It is ranked as one of Iran's top medical schools, with more than 9000 students studying in over 200 different disciplines, and a faculty staff of nearly 900 and 25,000 personnel.[citation needed] as it is one of the best medical universities in Iran.
Well said WH, Well said!!!!!!!
Did you put up this before?
Ragwitek by Merck & Co, Inc, and Catalent Pharma
October 7, 2014
Michael R. Page, PharmD, RPh
Pharmacy Times, October 2014 Diabetes, Volume 80, Issue 10
https://www.pharmacytimes.com/view/ragwitek-by-merck-and-co-inc-and-catalent-pharma
Very nice thanks Friend!! :)
Published: 26 November 2020
The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection
https://www.nature.com/articles/s41385-020-00359-2
Nasal Microbiota and Respiratory Tract Infections: The Role ...
www.atsjournals.org › doi › pdf
University of Bern Bern, Switzerland ORCID IDs: 0000-0002-6184-5280 (I.K.); 0000-0002-5239-1571 (P.L.). ... Sanders EA, Montijn R, Veenhoven RH, Keijser BJ, et al ..
https://www.atsjournals.org/doi/pdf/10.1164/rccm.201710-2020LE
Weill Cornell | Newsroom
news.weill.cornell.edu › tags › weill-cornell
Dr. Rogier Sanders, adjunct assistant research professor of microbiology and immunology at Weill Cornell Medical College Dr. Rogier Sanders, adjunct assistant research professor of microbiology and immunology and a member of Dr. John Moore's lab, won the 2011 NVBMB Prize from the Netherlands Society for Biochemistry and Molecular Biology.
https://news.weill.cornell.edu/tags/weill-cornell
Mapping Severe COVID-19 in the Lungs at Single-Cell Resolution
Posted on April 13th, 2021 by Dr. Francis Collins
https://directorsblog.nih.gov/2021/04/13/mapping-severe-covid-19-in-the-lungs-at-single-cell-resolution/
Mark Christopher Lincoln PHD HOUSTON METHODIST RESEARCH INSTITUTE
https://public.era.nih.gov/pubroster/preSepIndex.era?AGENDA=409399&CID=100239
Christopher Lincoln, PhD
Director, Office of Translational Production & Quality
Director, cGMP Core
The cGMP Core, comprised of Quality Assurance, Quality Control and Quality Operations, serves as the Quality Unit for the Office of Translational Production & Quality at the Houston Methodist Research Institute. Our mission is to provide internal investigators and external academic or industry partners with a cGMP compliant and cost-effective route to translating novel therapeutics and devices to the clinic.
Most academic institutions and small biotechnology companies outsource GMP manufacturing to contract manufacturing organizations, which can be very costly and time-consuming. Our infrastructure is designed to provide not only the Quality Systems, facilities and equipment for cGMP manufacturing and release, but also the expertise to guide and implement GMP protocols for investigators who may be less experienced in the process.
https://www.houstonmethodist.org/research/our-research/cores/translational-production-quality/
This comes from MERCK QUOTE!!
we suggest that the findings described in this study are broadly applicable to any Pichia strains used for the production of therapeutic proteins, including monoclonal antibodies, Fc fusions, peptides, hormones, and growth factors.
With a completely reengineered and humanized glycosylation pathway, glycoengineered Pichia pastoris has emerged as a promising production host for the manufacture of therapeutic glycoproteins.
https://pubmed.ncbi.nlm.nih.gov/25344235/
MERCK
This
reduction of O-glycosylation represents an important step
forward for the Pichia pastoris production platform as a suitable
system for the production of therapeutic glycoproteins.
https://storage.googleapis.com/plos-corpus-prod/10.1371/journal.pone.0068325/1/pone.0068325.pdf?X-Goog-Algorithm=GOOG4-RSA-SHA256&X-Goog-Credential=wombat-sa%40plos-prod.iam.gserviceaccount.com%2F20210424%2Fauto%2Fstorage%2Fgoog4_request&X-Goog-Date=20210424T025607Z&X-Goog-Expires=3600&X-Goog-SignedHeaders=host&X-Goog-Signature=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
One vaccine is based on a yeast-derived (Pichia pastoris) recombinant protein comprised of the receptor binding domain (RBD) of the SARS-CoV formulated on alum and referred to as the CoV RBD219-N1 Vaccine. Potentially this vaccine could be used as a heterologous vaccine against COVID-19.
https://www.preprints.org/manuscript/202003.0464/v1
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162542657
Virology
. 2019 Jan 2;526:125-137. doi: 10.1016/j.virol.2018.10.005. Epub 2018 Oct 26.
Development of a universal influenza vaccine using hemagglutinin stem protein produced from Pichia pastoris
Shih-Chi Wang 1, Hsin-Yu Liao 2, Jia-Yan Zhang 2, Ting-Jen Rachel Cheng 3, Chi-Huey Wong 4
https://pubmed.ncbi.nlm.nih.gov/30388628/
Pichia pastoris is a species of methylotrophic yeast. It was found in the 1960s, with its feature of using methanol, as a source of carbon and energy.[1] After years of study, P. pastoris was widely used in Biochemical research and Biotech industries.
https://en.wikipedia.org/wiki/Pichia_pastoris
Highlights
•
The expression of HPV 16 and 18 L1 proteins was high enough in Pichia pastoris to permit efficient purification.
•
The physicochemical and immunological properties of L1 antigens are characterized.
•
Pichia vaccine demonstrates good immune responses in mice & non-human primates, similar to Gardasil.
Physicochemical characterization and immunological properties of Pichia pastoris based HPV16L1 and 18L1 virus like particles
Author links open overlay panel Gaurav Guptaa bReinhard Glueck a Narayan Rishib
a
Department of Virology & Biotechnology, Vaccine Technology Centre, Zydus Biologics Compound, Sarkhej Bavla NH No 8 A, Changodar, Ahmedabad, 382213, Gujarat, India
b
Amity Institute of Virology and Immunology, Amity University, Noida, 201303, Uttar Pradesh, India
https://www.sciencedirect.com/science/article/abs/pii/S1045105616301543
Novel Influenza HA Vaccine Design
HA RBD / Monomeric RBD
https://www.who.int/immunization/research/meetings_workshops/23_Universal_flu.pdf
Emilie Seydoux
Fred Hutchinson Cancer Research Center, Seattle
Verified email at fredhutch.org
Vaccine development
Look at all the White Papers this gal has with People from University of Bern. Paper with Mario!!
https://scholar.google.com/citations?user=ESyIlwcAAAAJ&hl=en
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES SPECIAL EMPHASIS PANEL
ZAI1 CD - A (C4)
PRECLINICAL AND TRANSLATIONAL VACCINE DEVELOPMENT SUPPORT FOR HIV AND OTHER CANDIDATE AGENTS (PTVDS) (N01), TASK AREA G
12/08/20 - 12/08/20
Meeting Roster
CHAIRPERSON
----------------------
LINCOLN, CHRISTOPHER MARK, PHD
DIRECTOR, CGMP CORE
HOUSTON METHODIST RESEARCH INSTITUTE
HOUSTON, TX, 77030
MEMBERS
--------------
AMACKER, MARIO, PHD
HEAD OF QUALITY AND MANUFACTURING
MYMETICS SA
CH-1066 EPALINGES
DEMURIA, DEBORAH, PHMD
SENIOR REGULATORY AFFAIRS CONSULTANT
SENIOR REGULATORY AFFAIRS CONSULTANT
SOUTHBOROUGH, MA, 01772
SCULL, CHRISTOPHER MATTHEW, PHD
SENIOR CONSULTANT
BIOLOGICS CONSULTING
ROCKVILLE, MD, 20850
PROGRAM REPRESENTATIVE
--------------------------------------------
PENSIERO, MICHAEL N., PHD
PROGRAM OFFICER
VACCINE TRANSLATIONAL RESEARCH BRANCH (VTRB)
DIVISION OF AIDS
NATIONAL INSTITUTES OF HEALTH/NIAID
ROCKVILLE, MD, 20852
CONTRACT REPRESENTATIVE
----------------------------------------------
PATEL, KISHAN K.
CONTRACTING OFFICER
AIDS RESEARCH CONTRACTS BRANCH
OFFICE OF ACQUISITIONS
DIVISION OF EXTRAMURAL ACTIVITIES
NATIONAL INSTITUTE OF HEALTH/NIAID
ROCKVILLE, MD, 20852
SCALA, MICHELLE L.
CONTRACTING OFFICER, LEAD
AIDS RESEARCH CONTRACTS BRANCH
OFFICE OF ACQUISITIONS
DIVISION OF EXTRAMURAL ACTIVITIES
NATIONAL INSTITUTES OF HEALTH/NIAID
ROCKVILLE, MD, 20852
SCIENTIFIC REVIEW OFFICER
--------------------------------------------------
DE LA FUENTE, CYNTHIA L., PHD
SCIENTIFIC REVIEW OFFICER
AIDS REVIEW BRANCH
SCIENTIFIC REVIEW PROGRAM
DIVISION OF EXTRAMURAL ACTIVITIES
NATIONAL INSTITUTES OF HEALTH/NIAID
ROCKVILLE, MD, 20852
EXTRAMURAL SUPPORT ASSISTANT
--------------------------------------------------------
CRAWFORD, KAMESHA C.
PROGRAM SPECIALIST
AIDS REVIEW BRANCH
SCIENTIFIC REVIEW PROGRAM
DIVISION OF EXTRAMURAL ACTIVITIES
NATIONAL INSTITUTES OF HEALTH/NIAID
ROCKVILLE, MD, 20852
https://public.era.nih.gov/pubroster/preSepIndex.era?AGENDA=409399&CID=100239
Design of a highly thermotolerant, immunogenic SARS-CoV-2 ...
pubmed.ncbi.nlm.nih.gov › 33429215
We describe a monomeric, glycan-engineered RBD protein fragment that is expressed at a purified yield of 214 mg/l in unoptimized, mammalian cell culture and, in contrast to a stabilized spike ectodomain, is tolerant of exposure to temperatures as high as 100 °C when lyophilized, up to 70 °C in solution and stable for over 4 weeks at 37 °C.
Author: Sameer Kumar Malladi, Randhir Singh, Suman Pandey, Savitha Gayathri, Kawkab Kanjo, Shahbaz Ahmed, Mo...
Cited by: 4
Publish Year: 2021
Receptor Binding Domain (RBD) SARS-CoV-2, Monomeric
Made in CHO cells
In addition to stabilized trimeric spike proteins, we also offer the RBD domain produced in the same CHO cell system. The RBD protein is easier to produce and to purify and is therefore an ideal alternative for applications where costs are the driving factor. Please contact us to learn about our pricing per gram or mg of RBD protein.
https://www.excellgene.com/sars-cov-2-trimeric-spike-protein-rbd-monomer/
Specia - MDPI
www.mdpi.com › journal › processes
Prof. Dr. Florian M. Wurm Swiss Federal Institute of Technology Lausanne, Route Cantonale, 1015 Lausanne, Switzerland florian.wurm@epfl.ch Dr. Martin Jordan Merck Biopharma, Biotech Process Sciences, Corsier-sur-Vevey, Switzerland martin.jordan@merckgroup.com Deadline for manuscript submissions: closed (30 April 2019) Message from the Guest Editors
essage from the Guest Editors
This Special Issue of “Transient Gene Expression for Rapid
Protein and Virus-Vector supply” focuses on protein
production and on the generation of innovative virus
vectors for the widest range of applications in R&D and for
potential use in the clinic.
We encourage submissions of papers that present various
technologies, used with CHO, HEK-293, HeLa and other
mammalian or non-mammalian derived cell lines
providing access to rapid protein synthesis and to virus
vectors. The papers should emphasize readily applicable
methods, both for “standard” laboratories, but also for
more specialized use at scales of operation that exceed the
typical research laboratory (“large scale transient gene
expression”). In spite of the fact that virus-mediated
transfer of genetic information can be considered
transient, such as with the help of Baculovirus vectors, the
editors of this Special Issue wish to restrict the issue to
submissions of “naked” DNA or RNA as carriers the genes of
interests into the host cell system
rof. Dr. Florian M. Wurm
Swiss Federal Institute of
Technology Lausanne, Route
Cantonale, 1015 Lausanne,
Switzerland
florian.wurm@epfl.ch
Dr. Martin Jordan Merck Biopharma, Biotech
Process Sciences, Corsier-surVevey, Switzerland
martin.jordan@merckgroup.com
Deadline for manuscript
submissions:
closed (30 April 2019)
Mario Amacker
Sylvain Fleury
Recombinant PfCyRPA expressed in HEK 293 cells was chemically coupled to phosphoethanolamine and then incorporated into the membrane of unadjuvanted influenza virosomes approved as antigen delivery system for humans
https://www.researchgate.net/publication/338945184_Vaccination_with_virosomally_formulated_recombinant_CyRPA_elicits_protective_antibodies_against_Plasmodium_falciparum_parasites_in_preclinical_in_vitro_and_in_vivo_models
Mymetics SA · Quality Management - ResearchGate
www.researchgate.net › profile › Mario-Amacker
Florian M Wurm Although respiratory syncytial virus (RSV) causes severe lower respiratory tract infection in infants and adults at risk, no RSV vaccine is currently available
https://www.researchgate.net/profile/Mario-Amacker
Acknowledgements
We would like to express our thanks to our fellow PEVIA collaborators for their great work, as well as the Innovative Medicines Initiative, the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations for their support, and for allowing this project to happen.
We also thank the Secretariat for Education, Research and Innovation (SERI) in Bern, Switzerland, which provided funding to the research group of Prof. François Spertini at the Cantonal University Hospital of Vaud and also supported the work at ExcellGene.
https://www.excellgene.com/2020/04/subunit-vaccine-production-ebola-virus-case-study/
Antiviral properties of two trimeric recombinant gp41 proteins
www.ncbi.nlm.nih.gov › pmc › articles
Results. Two soluble trimeric recombinant gp41 proteins, termed Rgp41B and Rgp41A were designed. Both comprise the N- and C-terminal heptad repeat regions of the ectodomain of HIV-1 gp41, connected by a 7-residue hydrophilic linker, in order to mimic the trimeric fusogenic state of the transmembrane glycoprotein.
Author: Delphine Delcroix-Genête, Phenix-Lan Quan, Marie-Gaëlle Roger, Uriel Hazan, Uriel Hazan, Sébastien N...
Cited by: 5
MyMetics :: Randomized Phase I: Safety, Immunogenicity and ...
www.mymetics.com › media-center › randomized-phase-i-safety
The human immunodeficiency virus type 1 (HIV-1) is mainly transmitted through sexual contact. To infect its host, HIV-1 employs its viral membrane surface trimeric envelope glycoprotein, composed of the receptor binding domain gp120 and the membrane anchored fusion protein subunit gp41.
Check out the ref:
Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review.
Asadi K1, Gholami A2
Author information
International Journal of Biological Macromolecules, 15 Apr 2021, 182:648-658
DOI: 10.1016/j.ijbiomac.2021.04.005 PMID: 33862071
Review
Share this article Share with emailShare with twitterShare with linkedinShare with facebook
Abstract
Vaccination is the most effective means of controlling infectious disease-related morbidity and mortality. However, due to low immunogenicity of viral antigens, nanomedicine as a new opportunity in new generation of vaccine advancement attracted researcher encouragement. Virosome is a lipidic nanomaterial emerging as FDA approved nanocarriers with promising bioinspiration and biomimetic potency against viral infections. Virosome surface modification with critical viral fusion proteins is the cornerstone of vaccine development. Surface antigens at virosomes innovatively interact with targeted receptors on host cells that evoke humoral or cellular immune responses through antibody-producing B cell and internalization by endocytosis-mediated pathways. To date, several nanovaccine based on virosome formulations have been commercialized against widespread and life-threatening infections. Recently, Great efforts were made to fabricate a virosome-based vaccine platform against a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Thus, this review provides a novel overview of the virosome based nanovaccine production, properties, and application on the viral disease, especially its importance in SARS-CoV-2 vaccine discovery.
Full text links
Read article for free, from open access legal sources, via Unpaywall: https://doi.org/10.1016/j.ijbiomac.2021.04.005Unpaywall
Read article at publisher's site (DOI): 10.1016/j.ijbiomac.2021.04.005
References
Articles referenced by this article (88)
Development of Universal Influenza Vaccines Targeting Conserved Viral Proteins.
Jazayeri SD, Poh CL
Vaccines (Basel), (4) 2019
MED: 31683888
A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses.
Kammer AR, Amacker M, Rasi S, Westerfeld N, Gremion C, Neuhaus D, Zurbriggen R
Vaccine, (41):7065-7074 2007
MED: 17766014
https://europepmc.org/article/MED/33862071
Pandemic moves and countermoves: vaccines and viral variants
Rogier W Sanders
Menno D de Jong
Published: March 30, 2021
In summary, the early findings reported by Emary and colleagues suggest a meaningful degree of efficacy against the B.1.1.7 variant, which is encouraging. However, additional data are clearly needed to fully appreciate the potential impact of this and other variants of concern on current and future vaccine efficacy, and to provide conclusive evidence that will inform important policy projections and decisions. The COV002 study is ongoing and we eagerly await further data during this anxious time.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00730-3/fulltext
COV002 STUDY (University of Oxford)
https://clinicaltrials.gov/ct2/show/NCT04400838
Worldwide Provider of Clodronate Liposomes - Order Online
clodronateliposomes.com › new-project-at
Order Liposomes. Clodronate Liposomes; Control Liposomes (PBS) ... New project at University of Bern. New undisclosed project created on 2020-12-17 09:50:33. https://clodronateliposomes.com/contact/
NEW PROJECT AT UNIVERSITY OF BERN
New undisclosed project created on 2020-12-17 09:50:33
submitted by: University of Bern
In: Bern, CH
https://clodronateliposomes.com/new-project-at-university-of-bern/
COMPANY
Liposoma BV
Science Park 408
1098XH AMSTERDAM
The Netherlands
VAT: NL8524.12.551.B01
Commercial Chamber: 57037108
Phone: +31 (0)20 237 3600
https://www.liposomatechnology.com/
Pulmonary Delivery of Virosome-Bound Antigen Enhances Antigen-Specific CD4 + T Cell Proliferation Compared to Liposome-Bound or Soluble Antigen
Rebecca A M Blom 1 2 3, Mario Amacker 4, R Maarten van Dijk 5, Christian Moser 6, Philip A Stumbles 7 8, Fabian Blank 1 2, Christophe von Garnier 1 2
https://pubmed.ncbi.nlm.nih.gov/28439267/
Could virosome-based nanovaccines be a promising new approach ...
www.news-medical.net › news › 20210420
2 days ago · Researchers develop broad-spectrum SARS-CoV-2 RBD-based vaccine New COVID-19 vaccine could provide protection against existing and future strains of coronaviruses
https://www.news-medical.net/news/20210420/Could-virosome-based-nanovaccines-be-a-promising-new-approach-to-preventing-viral-diseases.aspx
Rory de Vries, PhD, and Rik de Swart, PhD, at Erasmus in the Netherlands, 100% of the untreated ferrets were infected by their virus-shedding cagemates, approximating a setting like sharing a bed or close living conditions for people.
NEWS RELEASE 17-FEB-2021
Could a nasal spray prevent coronavirus transmission?
COLUMBIA UNIVERSITY IRVING MEDICAL CENTER
https://www.eurekalert.org/pub_releases/2021-02/cuim-can021621.php
Matrix-M adjuvanted virosomal H5N1 vaccine confers protection ...
onlinelibrary.wiley.com › doi › 10
Sofia E. Magnusson, Arwen F. Altenburg, Karin Lövgren Bengtsson, Fons Bosman, Rory D. de Vries, Guus F. Rimmelzwaan, Linda Stertman, Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice, Immunologic Research, 10.1007/s12026-018-8991-x, 66, 2, (224-233), (2018)
https://onlinelibrary.wiley.com/doi/10.1111/j.1750-2659.2011.00256.x
Kemper's better get going or he will be left in the dust!!
The Next Generation of COVID-19 Vaccines Could Be a Pill
https://www.healthline.com/health-news/the-next-generation-of-covid-19-vaccines-could-be-a-pill
I'd like to know where Corpus is/ Where's the BIG BONANZA?
https://www.unr.edu/Images/news/2016/March/The_Big_Bonanza.jpg
DABOS Jasper Bos StartLab Advisory Board (SAB)
https://startlab.biopole.ch/about/
ENTREPRENEURS’ CLUB/ Ronald Kempers